A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.
We propose an integrative, mechanistic model that integrates in vitro virology data, pharmacokinetics, and viral response to a combination regimen of a direct-acting antiviral (telaprevir, an HCV NS3-4A protease inhibitor) and peginterferon alfa-2a/ribavirin (PR) in patients with genotype 1 chronic...
Guardado en:
Autores principales: | Bambang S Adiwijaya, Tara L Kieffer, Joshua Henshaw, Karen Eisenhauer, Holly Kimko, John J Alam, Robert S Kauffman, Varun Garg |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1ebc60fb8b8d4ddcaf1eafea5ed2727d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Vicente Soriano, et al.
Publicado: (2022) -
Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
por: Abdulla M, et al.
Publicado: (2019) -
Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
por: Meritxell Llorens-Revull, et al.
Publicado: (2021) -
The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
por: Irina RUSU, et al.
Publicado: (2020) -
Effect of different direct-acting antiviral regimens for treatment of nondiabetic hepatitis C virus–infected Egyptian patients on insulin resistance and sensitivity
por: Tarek Yosef, et al.
Publicado: (2021)